Eli Lilly and major shareholder Lilly Endowment Inc Unloads 245,000 Shares (LLY)
Eli Lilly and (NYSE:LLY) major shareholder Lilly Endowment Inc sold 245,000 shares of the stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $62.68, for a total transaction of $15,356,600.00. Following the completion of the transaction, the insider now directly owns 133,825,804 shares of the company’s stock, valued at approximately $8,388,201,395. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
LLY has been the subject of a number of recent research reports. Analysts at Morgan Stanley reiterated an “underweight” rating on shares of Eli Lilly and in a research note on Monday, June 2nd. They now have a $48.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly and in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Finally, analysts at Argus reiterated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, April 29th. They now have a $64.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $60.46.
Eli Lilly and (NYSE:LLY) traded down 0.06% on Thursday, hitting $62.96. The stock had a trading volume of 2,587,318 shares. Eli Lilly and has a one year low of $47.53 and a one year high of $63.10. The stock has a 50-day moving average of $59.70 and a 200-day moving average of $56.78. The company has a market cap of $67.537 billion and a price-to-earnings ratio of 17.61.
Eli Lilly and (NYSE:LLY) last released its earnings data on Thursday, April 24th. The company reported $0.70 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.70. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.78 billion. During the same quarter in the previous year, the company posted $1.14 earnings per share. The company’s revenue for the quarter was down 16.4% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend is Wednesday, August 13th.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.